Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Net Cash Flow (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Net Cash Flow data on record, last reported at -$80.7 million in Q3 2025.

  • For Q3 2025, Net Cash Flow fell 331.29% year-over-year to -$80.7 million; the TTM value through Sep 2025 reached $67.2 million, up 509.75%, while the annual FY2024 figure was $8.9 million, 3370.31% up from the prior year.
  • Net Cash Flow reached -$80.7 million in Q3 2025 per ABEO's latest filing, down from $147.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $147.6 million in Q2 2025 and bottomed at -$80.7 million in Q3 2025.
  • Average Net Cash Flow over 5 years is $3.9 million, with a median of $1.5 million recorded in 2023.
  • The widest YoY moves for Net Cash Flow: up 991.78% in 2024, down 1135.96% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at -$5.9 million in 2021, then soared by 158.78% to $3.5 million in 2022, then soared by 180.17% to $9.8 million in 2023, then fell by 21.82% to $7.6 million in 2024, then plummeted by 1156.89% to -$80.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$80.7 million in Q3 2025, $147.6 million in Q2 2025, and -$7.4 million in Q1 2025.